Ulimorelin
Based on the favorable effects of ulimorelin on gastrointestinal
function in animal experiments and small clinical studies, ulimorelin
has progressed to randomized clinical trials for the treatment of
diabetic gastroparesis or POI. In patients with diabetic gastroparesis,
ulimorelin improved gastrointestinal symptoms, such as vomiting and loss
of appetite, while there were no significant differences in improving
gastrointestinal function between patients with IP who took ulimorelin
and those who took placebo [32]. For this reason, efficacy and the
risk of unexpected hypotension, its development for gastrointestinal
indications has been discontinued [33].